FAKTOR OPTIONSSCHEIN - MODERNA | Market Closed - Bid/Ask 14:27:20 2024-06-20 EDT | After market 15:59:48 | |||
| 3.48 EUR | +4.50% |
|
3.48 | 0.00% |
| Current month | -14.09% | ||
| 1 month | -4.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 3.48 | +4.50% |
| 24-06-19 | 3.33 | -3.39% |
| 24-06-18 | 3.447 | -8.10% |
| 24-06-17 | 3.751 | +0.86% |
| 24-06-14 | 3.719 | -8.98% |
Real-time BOERSE MUENCHEN
Last update June 20, 2024 at 02:27 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Goldman Sachs |
| WKN | GK0JBX |
| ISIN | DE000GK0JBX0 |
| Date issued | 2022-02-15 |
| Strike | 66.64 $ |
| Maturity | Unlimited |
| Parity | 18.22 : 1 |
| Emission price | 10.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.54 € |
|---|---|
| Lowest since issue | 1.148 € |
| Spread | 0.02 € |
| Spread % | 0.57% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Certificates
- Certificat
